Cargando…
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
BACKGROUND: Novel androgen receptor signaling inhibitors for prostate cancer (PC) impose the burden of self-administration on older patients overwhelmed by the requirement of many other concomitant medications. PATIENTS AND METHODS: This study evaluated the proportion of non-adherence in a 12-month...
Autores principales: | Rescigno, Pasquale, Maruzzo, Marco, Rebuzzi, Sara Elena, Murianni, Veronica, Cinausero, Marika, Lipari, Helga, Fratino, Lucia, Gamba, Teresa, De Giorgi, Ugo, Caffo, Orazio, Bimbatti, Davide, Dri, Arianna, Mosca, Alessandra, Giunta, Emilio Francesco, Ermacora, Paola, Vignani, Francesca, Msaki, Aichi, Bonifacio, Barbara, Lombardo, Valentina, Conteduca, Vincenza, Basso, Umberto, Fornarini, Giuseppe, Banna, Giuseppe Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732238/ https://www.ncbi.nlm.nih.gov/pubmed/35920559 http://dx.doi.org/10.1093/oncolo/oyac147 |
Ejemplares similares
-
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022) -
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022) -
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021) -
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2023) -
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
por: Stellato, Marco, et al.
Publicado: (2021)